Vania Januar1, Richard Saffery2, Joanne Ryan3. 1. Cancer & Disease Epigenetics, Murdoch Childrens Research Institute, & Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia and joanne.ryan@mcri.edu.au. 2. Cancer & Disease Epigenetics, Murdoch Childrens Research Institute, & Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia and. 3. Cancer & Disease Epigenetics, Murdoch Childrens Research Institute, & Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia and Inserm U1061, Hopital La Colombiere & Universite Montpellier, Montpellier, France joanne.ryan@mcri.edu.au.
Abstract
BACKGROUND: Several broad lines of evidence support the involvement of epigenetic processes in neurodevelopment and psychiatric disorders. Epigenetic disruption also provides a potential mechanism to account for the numerous gene-environment interactions that have been reported in association with neuropsychiatric phenotypes. METHODS: A review of the literature was performed with keywords 'depression', 'depressive disorder' or 'antidepressants' and 'DNA methylation', or 'epigenetics' in humans. Citations were limited to those written in English and published prior to July 2014. RESULTS: We present a summary of results to date. Most studies have focused on DNA methylation in various CNS or peripheral tissue, with almost universally small sample sizes. Although seven epigenome-wide association studies have now been reported, the majority of studies have used a candidate-gene approach. Three genes (SLC6A4, BDNF, NR3C1) have been investigated in more than one study, but replication of findings is generally lacking. CONCLUSIONS: Recent evidence provides insights to epigenetic processes in psychiatric disorders; however, replication is lacking and care must be taken in the interpretation of current findings. This applies to epigenetic epidemiology generally, which is subject to various limitations that no single approach can address in isolation. Due to limited focus of most depression studies to date, placing the findings within the broader context of mood disorder pathophysiology may prove challenging. However, identifying peripheral biomarkers for depressive disorder remains a tantalising possibility, especially given the potential for carefully-designed longitudinal studies with multiple biospecimens and ongoing advances in epigenetic technologies.
BACKGROUND: Several broad lines of evidence support the involvement of epigenetic processes in neurodevelopment and psychiatric disorders. Epigenetic disruption also provides a potential mechanism to account for the numerous gene-environment interactions that have been reported in association with neuropsychiatric phenotypes. METHODS: A review of the literature was performed with keywords 'depression', 'depressive disorder' or 'antidepressants' and 'DNA methylation', or 'epigenetics' in humans. Citations were limited to those written in English and published prior to July 2014. RESULTS: We present a summary of results to date. Most studies have focused on DNA methylation in various CNS or peripheral tissue, with almost universally small sample sizes. Although seven epigenome-wide association studies have now been reported, the majority of studies have used a candidate-gene approach. Three genes (SLC6A4, BDNF, NR3C1) have been investigated in more than one study, but replication of findings is generally lacking. CONCLUSIONS: Recent evidence provides insights to epigenetic processes in psychiatric disorders; however, replication is lacking and care must be taken in the interpretation of current findings. This applies to epigenetic epidemiology generally, which is subject to various limitations that no single approach can address in isolation. Due to limited focus of most depression studies to date, placing the findings within the broader context of mood disorder pathophysiology may prove challenging. However, identifying peripheral biomarkers for depressive disorder remains a tantalising possibility, especially given the potential for carefully-designed longitudinal studies with multiple biospecimens and ongoing advances in epigenetic technologies.
Authors: Zoe Sessions; Norberto Sánchez-Cruz; Fernando D Prieto-Martínez; Vinicius M Alves; Hudson P Santos; Eugene Muratov; Alexander Tropsha; José L Medina-Franco Journal: Drug Discov Today Date: 2020-09-30 Impact factor: 7.851
Authors: Peter D Fransquet; Paul Lacaze; Richard Saffery; John McNeil; Robyn Woods; Joanne Ryan Journal: Alzheimers Dement Date: 2017-11-08 Impact factor: 21.566
Authors: Jesem Douglas Yamall Orellana; Joseph Murray; Natália Peixoto Lima; Ricardo Tavares Pinheiro; Bernardo Lessa Horta Journal: Front Public Health Date: 2022-06-09
Authors: Olivera Story Jovanova; Ivana Nedeljkovic; Derek Spieler; Rosie M Walker; Chunyu Liu; Michelle Luciano; Jan Bressler; Jennifer Brody; Amanda J Drake; Kathryn L Evans; Rahul Gondalia; Sonja Kunze; Brigitte Kuhnel; Jari Lahti; Rozenn N Lemaitre; Riccardo E Marioni; Brenton Swenson; Jayandra Jung Himali; Hongsheng Wu; Yun Li; Allan F McRae; Tom C Russ; James Stewart; Zhiying Wang; Guosheng Zhang; Karl-Heinz Ladwig; Andre G Uitterlinden; Xiuqing Guo; Annette Peters; Katri Räikkönen; John M Starr; Melanie Waldenberger; Naomi R Wray; Eric A Whitsel; Nona Sotoodehnia; Sudha Seshadri; David J Porteous; Joyce van Meurs; Thomas H Mosley; Andrew M McIntosh; Michael M Mendelson; Daniel Levy; Lifang Hou; Johan G Eriksson; Myriam Fornage; Ian J Deary; Andrea Baccarelli; Henning Tiemeier; Najaf Amin Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: Juan Joseph Young; Tim Silber; Davide Bruno; Isaac Robert Galatzer-Levy; Nunzio Pomara; Charles Raymond Marmar Journal: Front Psychiatry Date: 2016-04-25 Impact factor: 4.157